A recent study confirmed that anti-SLA positive AIH patients more often require lifelong immunosuppression, need longer time to achieve disease remission, and can less frequently be weaned from corticosteroid treatment as compared to anti-SLA-negative patients [91]. This evidence concerns the gene SLA and autoimmune hepatitis.